Akebia Therapeutics (NASDAQ: AKBA) details Q3 2025 results

Rhea-AI Filing Summary

Akebia Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results for the third quarter ended September 30, 2025 and recent business highlights. The company issued the press release on November 10, 2025, and attached it as Exhibit 99.1. The report clarifies that the information in Item 2.02 and Exhibit 99.1 is being furnished rather than filed under the Exchange Act, so it is not subject to Section 18 liability and will only be incorporated into other SEC filings if specifically referenced. Akebia’s common stock, par value $0.00001 per share, trades on The Nasdaq Capital Market under the symbol AKBA.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001517022FALSE00015170222025-11-102025-11-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

FORM 8-K

_____________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 10, 2025

_____________________

AKEBIA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

_____________________

Delaware

001-36352

20-8756903

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

245 First Street Cambridge, Massachusetts						02142
(Address of principal executive offices)						(Zip Code)

Registrant’s telephone number, including area code: (617) 871-2098

N/A

(Former name or former address, if changed since last report)

_____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.00001 per share

AKBA

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.    Results of Operations and Financial Condition.

On November 10, 2025, Akebia Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025 and recent business highlights. A copy of the Company’s press release containing this information is furnished as Exhibit 99.1 to this Current Report on Form 8-K (“Report”) and is incorporated herein by reference.

The information in this Report (including Item 2.02 and Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release, dated November 10, 2025, issued by Akebia Therapeutics, Inc.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						AKEBIA THERAPEUTICS, INC.
Date: November 10, 2025			By:			/s/ John P. Butler
						Name: John P. Butler
						Title: President and Chief Executive Officer

FAQ

What did Akebia Therapeutics (AKBA) report in this 8-K filing?

Akebia Therapeutics, Inc. furnished a press release announcing its financial results for the third quarter ended September 30, 2025 and recent business highlights, attaching the release as Exhibit 99.1.

What period do Akebia Therapeutics' latest results in this filing cover?

The financial results referenced in the filing relate to Akebia Therapeutics’ third quarter ended September 30, 2025.

How did Akebia Therapeutics provide its Q3 2025 results to investors?

The company issued a press release on November 10, 2025 detailing its Q3 2025 financial results and business highlights, and furnished that press release as Exhibit 99.1 to the current report.

Is the Akebia Therapeutics Q3 2025 press release considered filed with the SEC?

The report states that the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, unless specifically incorporated by reference in another filing.

On which exchange is Akebia Therapeutics (AKBA) common stock listed?

Akebia Therapeutics’ common stock, par value $0.00001 per share, is listed on The Nasdaq Capital Market under the trading symbol AKBA.

What exhibits are included with this Akebia Therapeutics 8-K?

The filing lists Exhibit 99.1, a press release dated November 10, 2025 from Akebia Therapeutics, Inc., and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.